Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

601
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
601
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

467
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
467
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

508
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
508
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

619
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
619
Aneurysm I: Introduction01:30

Aneurysm I: Introduction

413
An aortic aneurysm is a localized outpouching or dilation at a weak point in the artery wall. It may involve different parts of the aorta, such as the abdominal aorta, aortic arch, or thoracic aorta.Etiological factorsSeveral disorders are associated with aortic aneurysms.Congenital causes, such as primary connective tissue disorders like Marfan syndrome, impact the integrity and strength of connective tissues, notably affecting the aorta. Marfan syndrome is a genetic disorder that specifically...
413
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

532
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
532

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Rupture of Intercostal Aneurysm Associated with von Recklinghausen's Disease:Report of a Case].

Kyobu geka. The Japanese journal of thoracic surgery·2026
Same author

Thoracic Aortic Aneurysm Following Blunt Trauma in a Patient with a Monoallelic <i>SLC2A10</i> Variant: A Case Report.

Annals of vascular diseases·2026
Same author

[Cardiac Cavernous Hemangioma in the Right Atrium:Report of a Case].

Kyobu geka. The Japanese journal of thoracic surgery·2025
Same author

[Uterine Intravenous Leiomyomatosis with Right Ventricular Extension:Report of a Case].

Kyobu geka. The Japanese journal of thoracic surgery·2025
Same author

Preoperative Blood Lactate Level as a Simple Point-of-Care Predictor of Surgical Mortality in Acute Type A Aortic Dissection.

Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia·2025
Same author

Isolated Cleft of the Posterior Mitral Valve Leaflet With Papillary Muscle Abnormalities.

Circulation reports·2025

Related Experiment Video

Updated: Jan 31, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.1K

[Idiopathic Pulmonary Artery Aneurysm].

Kentoku Fukuoka1, Kei Aizawa, Akira Sugaya

  • 1Department of Cardiothoracic Surgery, Jichi Medical University, Shimotsuke, Japan.

Kyobu Geka. the Japanese Journal of Thoracic Surgery
|December 28, 2018
PubMed
Summary

Idiopathic pulmonary artery aneurysm (PAA) is rare. This case details surgical repair of a 60 mm PAA in a 72-year-old man, highlighting successful treatment for this uncommon condition.

More Related Videos

Arterial Pouch Microsurgical Bifurcation Aneurysm Model in the Rabbit
06:11

Arterial Pouch Microsurgical Bifurcation Aneurysm Model in the Rabbit

Published on: May 14, 2020

2.8K
Fluorescence Angiography for Evaluation of Aneurysm Perfusion and Parent Artery Patency in Rat and Rabbit Aneurysm Models
04:08

Fluorescence Angiography for Evaluation of Aneurysm Perfusion and Parent Artery Patency in Rat and Rabbit Aneurysm Models

Published on: July 24, 2019

7.5K

Related Experiment Videos

Last Updated: Jan 31, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.1K
Arterial Pouch Microsurgical Bifurcation Aneurysm Model in the Rabbit
06:11

Arterial Pouch Microsurgical Bifurcation Aneurysm Model in the Rabbit

Published on: May 14, 2020

2.8K
Fluorescence Angiography for Evaluation of Aneurysm Perfusion and Parent Artery Patency in Rat and Rabbit Aneurysm Models
04:08

Fluorescence Angiography for Evaluation of Aneurysm Perfusion and Parent Artery Patency in Rat and Rabbit Aneurysm Models

Published on: July 24, 2019

7.5K

Area of Science:

  • Cardiology
  • Thoracic Surgery
  • Vascular Medicine

Background:

  • Idiopathic pulmonary artery aneurysm (PAA) is a rare condition, often associated with other cardiovascular or connective tissue disorders.
  • This case focuses on a patient with no known underlying conditions contributing to the aneurysm.

Observation:

  • A 72-year-old male presented with a gradually expanding idiopathic PAA, initially diagnosed at 37 mm.
  • The aneurysm reached a significant size of 60 mm, necessitating surgical intervention.

Findings:

  • Surgical resection of the 60 mm idiopathic PAA was successfully performed.
  • Reconstruction utilized a 24 mm expanded polytetrafluoroethylene graft.

Implications:

  • This case demonstrates the feasibility and success of surgical management for large idiopathic PAAs.
  • Effective treatment options exist for idiopathic PAA, even in advanced stages, ensuring positive patient outcomes.